NICE backs broad use for Gilead/Galapagos arthritis pill JyselecaPatients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ Share XNICE backs broad use for Gilead/Galapagos arthritis pill Jyselecahttps://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/
NHS and Kite sign access deal for Kite’s cancer cell therapy TecartusNHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell Share XNHS and Kite sign access deal for Kite’s cancer cell therapy Tecartushttps://pharmaphorum.com/news/nhs-kite-cancer-therapy/
High hopes as Inventiva takes NASH contender into phase 3Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, Share XHigh hopes as Inventiva takes NASH contender into phase 3https://pharmaphorum.com/news/high-hopes-as-inventiva-takes-nash-contender-into-phase-3/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
The top 5 pharma M&A deals of 20202020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout Share XThe top 5 pharma M&A deals of 2020https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/
Lilly’s baricitinib granted US emergency use in COVID-19Doctors in the US are to get another option to treat COVID-19 after the FDA granted an Emergency Share XLilly’s baricitinib granted US emergency use in COVID-19https://pharmaphorum.com/news/lillys-baricitinib-granted-us-emergency-use-in-covid-19/
ViiV could challenge Gilead with long-acting HIV PrEP shotGlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after Share XViiV could challenge Gilead with long-acting HIV PrEP shothttps://pharmaphorum.com/news/viiv-could-challenge-gilead-with-long-acting-hiv-prep-shot/
Gilead and Novo plot next steps after trial data from NASH comboGilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked Share XGilead and Novo plot next steps after trial data from NASH combohttps://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/
Gilead’s remdesivir finally gets US approvalGilead’s Veklury (remdesivir) has become the first COVID-19 drug approved in the US following a nod from the Share XGilead’s remdesivir finally gets US approvalhttps://pharmaphorum.com/news/gileads-remdesivir-finally-gets-us-approval/